Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. We are developing a powerful new class of potent, specific and versatile small protein therapies called DARPins.

We’re called Molecular Partners for a reason.
Partnership is the core value that defines our company, our research and our product candidates.
Our management team includes many of the scientists who discovered DARPins at the University of Zurich, and we continue to bring together talented individuals from many disciplines who share our commitment to developing breakthrough medicines for serious diseases.
Our multi-benefit DARPins also function as a team, combining multiple small proteins with high-specificity, potency and versatility in one therapy. This approach allows us to design medicines that can inhibit multiple disease-specific targets and may improve outcomes for patients living with cancer and sight-threatening diseases and other disorders.
We work with industry leaders in the fields of ophthalmology, oncology and immunology to leverage the full potential and reach of our multi-benefit DARPin platform, creating value for both sides of each partnership.